WO2011142543A2 - 아텔로콜라겐 분리방법 및 개질된 아텔로콜라겐 제조방법 그리고 이를 이용하여 제조된 아텔로콜라겐 및 콜라겐 기반 매트릭스 - Google Patents
아텔로콜라겐 분리방법 및 개질된 아텔로콜라겐 제조방법 그리고 이를 이용하여 제조된 아텔로콜라겐 및 콜라겐 기반 매트릭스 Download PDFInfo
- Publication number
- WO2011142543A2 WO2011142543A2 PCT/KR2011/002903 KR2011002903W WO2011142543A2 WO 2011142543 A2 WO2011142543 A2 WO 2011142543A2 KR 2011002903 W KR2011002903 W KR 2011002903W WO 2011142543 A2 WO2011142543 A2 WO 2011142543A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- atelocollagen
- atelo
- atelo collagen
- solution
- Prior art date
Links
- 108010045569 atelocollagen Proteins 0.000 title claims abstract description 256
- 238000000926 separation method Methods 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 68
- 102000008186 Collagen Human genes 0.000 title claims description 108
- 108010035532 Collagen Proteins 0.000 title claims description 108
- 229920001436 collagen Polymers 0.000 title claims description 108
- 239000011159 matrix material Substances 0.000 title claims description 38
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 20
- 238000011026 diafiltration Methods 0.000 claims abstract description 12
- 239000012528 membrane Substances 0.000 claims description 65
- 238000001914 filtration Methods 0.000 claims description 54
- 238000004519 manufacturing process Methods 0.000 claims description 41
- 239000006185 dispersion Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000010613 succinylation reaction Methods 0.000 claims description 27
- 230000035322 succinylation Effects 0.000 claims description 26
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 18
- 229940014800 succinic anhydride Drugs 0.000 claims description 18
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 230000007935 neutral effect Effects 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 14
- 238000004132 cross linking Methods 0.000 claims description 13
- 238000004062 sedimentation Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 238000001467 acupuncture Methods 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 230000037319 collagen production Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000010030 laminating Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 16
- 239000012535 impurity Substances 0.000 abstract description 13
- 239000000243 solution Substances 0.000 description 67
- 210000004379 membrane Anatomy 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 238000000746 purification Methods 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 102000012422 Collagen Type I Human genes 0.000 description 12
- 108010022452 Collagen Type I Proteins 0.000 description 12
- 102000057297 Pepsin A Human genes 0.000 description 12
- 108090000284 Pepsin A Proteins 0.000 description 12
- 229940111202 pepsin Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 241000724675 Hepatitis E virus Species 0.000 description 6
- 241000710842 Japanese encephalitis virus Species 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249987—With nonvoid component of specified composition
- Y10T428/249988—Of about the same composition as, and adjacent to, the void-containing component
Definitions
- the present invention relates to a method for separating atelocollagen and high purity atelo collagen prepared by using the same. More specifically, atelocollagen is economically separating high purity atelocollagen from animal tissues by removing impurities efficiently and conveniently. It relates to a separation method and high purity atelo collagen prepared using the same.
- the present invention relates to a method for producing modified atelocollagen, which is dissolved in a neutral solution and has excellent biocompatibility, and thus can be applied to various formulations, and a modified atelocollagen prepared using the same.
- the present invention relates to a collagen-based matrix having a three-dimensional matrix structure and a method for producing the same by using the atelocollagen and the modified atelocollagen as described above to improve the mechanical strength by making a hard layer and a porous layer and crosslinking them. It is about.
- collagen or fibrinocytes contain a peptide (so-called "RGD peptide") sequence consisting of arginine-glycine-aspartic acid that induces cell adhesion.
- RGD peptide a peptide sequence consisting of arginine-glycine-aspartic acid that induces cell adhesion.
- Artificially arranging the RGD peptide on the surface of the biomaterial provides an environment that induces adhesion between the surface of the biomaterial and the cell, thereby mimicking the function of natural tissue by combining the surface of the biomaterial with the surrounding cells.
- collagen is one of the very important natural materials among the various natural polymers described above. This is because collagen, which is distributed in almost all tissues in vivo, is an essential protein for building a living body by forming and maintaining organs and tissues in combination with cells as a structure for supporting and proliferating cells.
- Collagen is a major protein component of the extra-cellular matrix, and it is contained in soft tissues such as bones and teeth as well as soft tissues including connective tissues such as skin, tendons, and blood vessels. It takes about one third of the protein, has a certain order, and the cells gather to form the basic structure of tissues or organs. Without collagen, multicellular animals cannot exist. Therefore, when trying to regenerate a damaged part of a living body to its original tissue, if the extracellular matrix of the tissue is supplied to the damaged part, the tissue cell will have regeneration ability, thus providing collagen as a basic matrix of the artificial tissue substitute. It is very advantageous.
- type 1 collagen is most widely used in tissue engineering because it is contained in almost all tissues such as skin, ligaments and bones.
- telopeptide that does not form a helix at both ends of the collagen type 1 molecule, which is the main cause of the immune response.
- Atelocollagen is used.
- the type 1 collagen separation method that is generally used up to now is treated with trypsin to separate animal cells from cells, remove minerals and various glycoproteins from the extracellular matrix, and utilize the intrinsic polarity or acid solubility of collagen.
- trypsin to separate animal cells from cells, remove minerals and various glycoproteins from the extracellular matrix, and utilize the intrinsic polarity or acid solubility of collagen.
- a precipitation method to separate type 1 collagen in this manner, a precipitation method, a chromatography method using a urea buffer solution, and a centrifugation method are conventionally used.
- pepsin is treated to remove telopeptides that cause an immune reaction. have.
- the conventional type 1 collagen separation method since the conventional type 1 collagen separation method has to go through a multi-step process, the separation process is inconvenient, time-consuming and expensive, as well as the urea used to separate type 1 collagen. In addition, there is a problem in that separation and inactivation of pepsin used for telopeptide removal are necessary. That is, the conventional type 1 collagen separation method makes the separation process more complicated and difficult, and makes it difficult to economically obtain high-purity type 1 collagen.
- biomaterials using collagen still have limitations for use in human tissues due to their low tensile strength and biodegradable properties.
- the Republic of Korea Patent No. 10-0465015 is a high purity type 1 collagen by removing the non-collagen substances through the enzyme treatment to reduce the immunity and extract and remove fatty impurities and insoluble collagen using an organic solvent The manufacturing method is described.
- the organic solvent is used as in the Republic of Korea Patent No. 10-0465015, there may be a degeneration of collagen and the use of an organic solvent that is harmful to the human body may cause side effects when the separated collagen is applied in vivo. .
- the Republic of Korea Patent No. 10-0676285 in the bone tissue, cartilage tissue, skin tissue, tendon / tendon tissue of the pig powdered or fragmented and acid treatment and then repeatedly treated pepsin to isolate the type 1 collagen primary
- a method of separating the precipitated collagen by centrifugation after neutralization at a low temperature of 30 to 37 ° C. after repeating the three steps of salt treatment and neutral titration is performed.
- the separation method of the Republic of Korea Patent No. 10-0676285 may be advantageous in terms of removing fat or insoluble substances while preventing the denaturation of collagen, but the salt treatment process and the titration process to neutral are complicated and multiply first. There was a problem that is inadequate to economically separate the type collagen yield.
- Korean Patent Laid-Open Publication No. 10-2002-0029859 discloses a method for producing atelocollagen, which is treated by enzymatic treatment and then purified by a conventional method immediately after pulverizing soft tissues or hard tissues of mammals in an acid solution.
- this technique also has the advantage of simplifying the process of the previous stage of the separation and purification process, but the method of increasing the purity by using dialysis and filtration in the subsequent separation and purification process.
- the extraction process of collagen has been performed using dialysis, multiple filtration, or various pore sizes in the process of increasing the purity by removing various impurities from the collagen separated from animal tissues.
- I was using a method of overlapping three or four filters.
- the dialysis method was limited in increasing purity due to the limited membrane pore size of 12,000 ⁇ 14,000 Daltons, and it was not possible to reuse multiple filters with different pore size.
- the use of expensive filters has the disadvantage of high cost.
- the present inventors provide a separation method in which an ultrafiltration and diafiltration method using a reusable filter is fused to provide high purity even through a single process line.
- a method of extracting collagen was developed.
- the present inventors have developed a method for producing modified atelocollagen, which is dissolved in a neutral solution and has excellent biocompatibility and can be applied to various formulations. Without collagen, it can be applied to various fields such as cosmetics, medicine, and food.
- the present inventors have introduced a porous matrix manufacturing technique in which a collagen is made of a two-layer structure (two collagen layers having different porosities) of a hard layer and a porous layer and crosslinked into the above-described technique to improve mechanical strength.
- the fabrication of the dimensional matrix structure solved the low tensile strength and biodegradation problem of collagen.
- An object of the present invention is to provide an atelocollagen separation method for efficiently and conveniently removing impurities and economically separating high-purity atelocollagen from animal tissues, and to provide high-purity atelocollagen prepared using the same.
- the present invention is a modified atel collagen production method and modified atel prepared using the improved ease of use that can be applied to a variety of formulations by modifying the water-soluble collagen dissolved in a neutral solution to improve biocompatibility Its purpose is to provide collagen.
- the present invention is a three-dimensional that improves the mechanical strength by making a hard layer and a porous layer (two collagen layers with different porosities) and crosslinking them using atelocollagen and modified atelocollagen as described above. It is an object of the present invention to provide a collagen-based matrix having a matrix structure and a method of preparing the matrix.
- ultrafiltration used in the specification of the present invention is a filtration method located in the middle of microfiltration and reverse osmosis, and removes low-molecular substances from the polymer solution, but not a difference in concentration across the filtration membrane. By means of separating and filtering the material using. Filtration membranes used for ultrafiltration have pores of various sizes depending on the material to be separated.
- diafiltration used in the specification of the present invention means that in the ultrafiltration, materials larger than the pores of the filtration membrane are concentrated in the relation of the feed, the residue, and the filtrate. Some of the desired substances to be filtered remain in the residue to be concentrated. The ratio of the desired substances to be gradually refined by returning them back to the feed side and adding purified water, etc., and concentrating them again through the filtration membrane. It means how to increase.
- the sample containing the atelo collagen is introduced into the filtration module having the filtration membrane from the container by the pumping action by the pump in the step (b).
- the filtration module is characterized in that to apply a pressure of about 10 ⁇ 30psi.
- the ultrafiltration process is stopped when the ultrafiltration rate is reduced to about 1 g / min or less in the step (e).
- the same amount of purified water as the solution filtered through the ultrafiltration process may be added to the residue returned to the vessel in the step (f).
- the diafiltration process may be performed at least five times.
- atelocollagen of an embodiment of the present invention is prepared according to the atelocollagen separation method as described above.
- step (c) maintaining the reaction solution of the atelo collagen and succinic anhydride stirred in step (b) at a pH of about 9 to 10 for a predetermined time;
- the step (b) and the step (c) may be repeated at least four times.
- the succinylation atelo collagen production method of an embodiment of the present invention may further comprise the step of washing the succinylation atelo collagen sedimentation with acidic distilled water.
- the method for preparing succinylation atelo collagen according to an embodiment of the present invention may further include lyophilizing the succinylation atelo collagen sedimentation.
- the succinylation atelo collagen of an embodiment of the present invention is prepared by the succinylation atelo collagen production method as described above.
- step (b) making the atelo collagen dispersion stirred in step (a) to approximately neutral state
- step (c) centrifuging the atelocollagen dispersion in a substantially neutral state in step (b) to obtain esterified atelocollagen sedimentation;
- step (d) putting the esterified atelo collagen sediment obtained in step (c) into a dialysis membrane to perform dialysis in purified water.
- the method for preparing esterified atelo collagen according to one embodiment of the present invention may further include lyophilizing the esterified atelo collagen sediment dialyzed in step (d).
- esterified atelo collagen of an embodiment of the present invention is prepared by the esterified atelo collagen production method as described above.
- step (d) secondly bonding the collagen hard layer and the collagen porous layer by crosslinking the collagen hard layer and the collagen porous layer primarily bonded through the step (c) using a crosslinking means. It includes.
- the method for producing a collagen-based matrix of an embodiment of the present invention further includes the step of (e) washing the crosslinking agent when the crosslinking means is a crosslinking agent.
- the bilayer of the collagen hard layer and the collagen porous layer may be further lyophilized.
- the pressure applied to the porous adsorption plate in the step (b) is preferably 1 ⁇ 20psi.
- the crosslinking means is characterized in that EDC [1-ethyl-3- (3-dimethyl aminopropyl) carbodiimide] or glutaraldehyde.
- hyaluronic acid may be added to the atelo collagen dispersion used in step (a).
- the collagen-based matrix of an embodiment of the present invention is prepared by the method for producing a collagen-based matrix as described above.
- atelocollagen separation method of the present invention an efficient and simple removal of impurities through a single process line using a separation method that combines ultrafiltration and diafiltration using a reusable filter.
- High purity atelo collagen can be isolated and economically extracted from animal tissues.
- modified atelocollagen which is dissolved in a neutral solution and has excellent biocompatibility, and thus can be easily applied to various formulations.
- Atelocollagen has the advantage that it can be applied to various fields such as cosmetics, medicines, and foods in its natural state without hydrolysis by the peptideization and enzyme treatment of collagen.
- the method for preparing a collagen-based matrix of the present invention by making the collagen into a two-layer structure (two collagen layers having different porosities) of a hard layer and a porous layer, and then crosslinking them to improve the mechanical strength of the collagen-based matrix
- the 3D porous collagen-based matrix prepared by such a manufacturing method has an advantage in that the porous membrane is partially destroyed and lost in the aqueous solution, and does not cause a problem of being easily separated from the hard layer.
- FIG. 1 is a block schematically showing a separation and purification apparatus 100 used for atelocollagen separation and purification using a separation method in which the ultrafiltration and diafiltration methods are fused in an atelocollagen separation method according to an embodiment of the present invention. It is also.
- FIGS. 2 and 3 are graphs and charts showing the results of quantifying atelo collagen after water removal of purified atelocollagen (sample concentration 0.5 mg / mL) through the atelocollagen separation method according to one embodiment of the present invention. to be.
- Figure 4 is after performing SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) on the purified purified atelocollagen by the atelocollagen separation method of an embodiment of the present invention, Coomasie Brilliant Blue (Coomasie Brilliant Blue)
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
- Coomasie Brilliant Blue Coomasie Brilliant Blue
- Figure 5 is an electrophoresis picture that confirmed that the collagen type is type 1 collagen by performing a Western blotting after performing electrophoresis on the purified atelo collagen separated by the atelocollagen separation method of an embodiment of the present invention.
- FIG. 6 is a graph showing a result of circular dichroism spectrum analysis of atelocollagen separated and purified by atelocollagen separation method according to an embodiment of the present invention.
- FIG. 7 and 8 show the results of quantifying pepsin to confirm whether pepsin used for telopeptide remains in purified atelo collagen separated by the atelocollagen separation method of an embodiment of the present invention. Graphs and charts.
- Figure 9 shows the results of performing real-time PCR to determine whether the HEV (Hepatitis E virus), a pig-derived virus, is detected in purified atelocollagen by the atelocollagen separation method of an embodiment of the present invention Data plot.
- HEV Hepatitis E virus
- FIG. 10 is a reverse transcriptase PCR (RT-PCR) method for confirming whether JEV (Japanese encephalitis virus), a pig-derived virus, is detected in purified atelocollagen by atelocollagen separation method according to an embodiment of the present invention.
- RT-PCR reverse transcriptase PCR
- FIG. 11 is a photograph comparing solubility of succinylated atelo collagen (anionized atelo collagen) obtained using the modified atelocollagen production method of an embodiment of the present invention with conventional atelo collagen.
- pig skin was prepared from animal tissues and washed with tap water.
- animal tissue various animal tissues containing collagen, for example, oxtail, pig cartilage tissue, bone tissue, dry cloth, and the like can be used.
- the washed pig skin was cut into 2 cm x 10 cm in size, and the cut pork skin was immersed in 0.1-1 M acetic acid solution, and then swelled at 4 ° C. for 16 to 24 hours. Fat and epidermis of swollen porcine skin tissue were removed with a knife, and tissues from which fat and epidermis were removed were cut to a size of 1 cm ⁇ 1 cm.
- tissue cut to a size of 1cm ⁇ 1cm was washed 5-10 times with purified water and then placed in 90-99% ethanol solution and stirred at 4 ° C. for 16-24 hours. Then, the tissue cut to a size of 1cm ⁇ 1cm was sieved to remove the ethanol solution, and then put again in 90 ⁇ 99% ethanol solution and stirred at 4 °C or more for 5 hours.
- the stirred and treated tissues in ethanol solution were sieved, immersed in 0.1-1 M acetic acid solution, and swelled for 20-60 minutes.
- the swollen tissue was blended with 0.1-1 M acetic acid solution.
- the blended tissues were homogenized using a homogenizer.
- Pepsin was treated to the solution obtained by performing the pretreatment in Example 1-1 and stirred at 4 ° C. for 24 to 72 hours, and then the pH of the solution was adjusted to 8 to inactivate pepsin.
- step 2) After centrifuging the solution obtained in step 1) at 7,000-15,000 g at 4 ° C. for 10-30 minutes, the upper layer of fat and lower impurities were removed and the solution of the middle layer was taken.
- step 4) The solution passed through step 3) was centrifuged to obtain extracted atelo collagen acupuncture.
- step 5 Atelo collagen acupuncture extracted in step 4) was added to a 90 ⁇ 99% ethanol solution and stirred for 16-24 hours at 4 °C.
- step 6) further centrifuging the solution passed through step 5) to obtain atelo collagen acupuncture, and repeating step 5) once more.
- step 2) The solution obtained through step 1) (hereinafter, referred to as "refined collagen solution”) is separated and purified through a single process line using a separation method that combines ultrafiltration and diafiltration.
- a separation and purification apparatus 100 as shown in FIG. 1 was prepared.
- the device of FIG. 1 may be manufactured directly or may be configured using a device (model name: CENTRASETTE TM System) sold by Pall corporation.
- step 7 In the ultrafiltration process of step 7), if the rate of the filtrate solution is reduced to approximately 1 g / min or less, the filtration is stopped.
- the yield and yield of atelo collagen by a single process using the separation and purification apparatus 100 shown in FIG. Separation purification is performed to increase the purity. That is, in the separation and purification apparatus 100 of FIG. 1, the residue which is not filtered through the filtration membrane in the filtration module 30 is transferred to the feed tank 10 at a constant flow rate through the remaining portion 35 of the filtration module 30. If the ultrafiltration rate decreases below a predetermined speed in step 8), the ultrafiltration is stopped and the diafiltration process for the residue returned to the feed tank 10 is subsequently performed. At this time, the same amount of purified water as the ultrafiltered solution is added to the residue returned to the feed tank 10, and diafiltration is performed five times or more using the separation and purification apparatus 100 shown in FIG.
- the atelo collagen solution obtained by ultrafiltration through step 7 and the atelo collagen solution obtained by diafiltration through step 9) was adjusted to pH 7.0, and then lyophilized to form a sponge. Atelo collagen is finally obtained.
- the atelocollagen separation and purification method of this embodiment can solve the problem of expensive purification and inconvenient purification by consuming a large number of expensive filters when multiple filters are overlapped. That is, the ultrafiltration using the reusable filter first purified some of the atelo collagen and based on the filtration rate, the efficiency of the ultrafiltration is judged to be low, and the filtration module 30 remains immediately without replacement of the filter or the rearrangement of the device. It can be used as diafiltration device for.
- the atelocollagen separation and purification method of the present embodiment is efficient and simple to remove impurities and economically removes atelocollagen from animal tissues through a single cyclic process line using the separation and purification apparatus 100 as shown in FIG. 1. It can be separated and extracted with high purity with good yield.
- Example 2 Analytical tests such as purity and safety of atelo collagen extracted and separated in Example 1
- Atelo collagen was quantified after water removal of the extracted and purified atelocollagen (sample concentration 0.5 mg / mL) in Example 1. As a result, as shown in Figures 2 and 3, it was confirmed that the purity of the atelo collagen separated and purified using the atelocollagen separation method of one embodiment of the present invention.
- pepsin was quantified to confirm whether or not pepsin used for telopeptide remained in the extracted and purified atelocollagen in Example 1. As a result, as shown in Figures 7 and 8 it was confirmed that pepsin is not detected in the atelo collagen separated and purified through the atelocollagen separation method of an embodiment of the present invention.
- the atelocollagen separation method of the present invention is an effective method for separation and purification with high purity while maintaining the atelocollagen from the animal tissues in an undenatured state.
- HEV Hepatitis E virus
- a pig-derived virus was detected in atelocollagen extracted and purified in Example 1.
- HEV Hepatitis E virus
- a pig-derived virus was confirmed to be negative, and HEV was not detected in the atelocollagen isolated and purified using the atelocollagen separation method of the embodiment of the present invention. It was known to be harmless.
- RT-PCR Reverse Transcriptase PCR
- atelocollagen isolated and purified using the atelocollagen separation method according to an embodiment of the present invention is removed from the telopeptide as type 1 collagen. It is a high purity atelocollagen free from used pepsin and other impurities, and has been shown to be safe in terms of the risk of infection with animal viruses. Therefore, atelocollagen separated and purified using the atelocollagen separation method of one embodiment of the present invention can be applied to various fields such as cosmetics, medicines, and foods in their natural state.
- a method for preparing succinylated atelo collagen and esterified atelo collagen which is a modified atelocollagen, which is dissolved in a neutral solution and is easy to be applied to various formulations, has improved usability and biocompatibility.
- the method for producing modified atelo collagen of the present invention is improved in terms of improving yield and increasing purity than conventional methods.
- Example 3-1 Method for preparing succinylation atelo collagen
- Method for producing succinylation atelo collagen of an embodiment of the present invention is as follows.
- step 2) To the atelo collagen solution obtained in step 1), succinic anhydride is added at a rate of about 0.8 to 1.3 g per 1 g of atelo collagen added in step 1), and 0.05 to 10 minutes. The pH is maintained around 9-10 with 1M NaOH.
- step 2) The solution obtained in step 2) is stirred at 4 ° C. for 30 minutes.
- step 4) The solution stirred in step 3) is maintained at around 9-10 pH for 10 minutes using 0.05 ⁇ 1M NaOH.
- step 5 The solution obtained in step 4) is stirred at 4 ° C. for 30 minutes.
- step 6) The solution stirred in step 5) is maintained at around 9-10 pH for 10 minutes using 0.05 ⁇ 1M NaOH.
- step 7) The solution obtained in step 6) is stirred at 4 ° C. for 20 minutes.
- step 8) The solution stirred in step 7) is maintained at around 9-10 pH for 10 minutes using 0.05 ⁇ 1M NaOH.
- step 9) The solution obtained in step 8) is stirred at 4 ° C. for 10 minutes.
- step 10) The solution stirred in step 9) is adjusted to pH 9-10 using 0.05-1M NaOH.
- step 11 The solution obtained in step 10) was adjusted to pH 4.03 with 3-7M HCl to form succinylated atelo collagen precipitate and stirred at 4 ° C. for 15 minutes.
- step 12 The solution stirred in step 11) is centrifuged to obtain succinylated atelo collagen sedimentation.
- step 13 Add distilled water adjusted to pH 4.03 using 3-7M HCl at a rate of about 20 mL per 1 g of atelo collagen added in step 1) to the atelo collagen acupuncture obtained in step 12), Wash by stirring at 4 ° C. for 15 minutes.
- step 14) The solution obtained in step 13) is centrifuged to obtain washed succinylated atelo collagen precipitate.
- a reaction scheme showing a reaction in which the atelo collagen is succinylated through the manufacturing process as described above is as follows.
- the stirred solution is maintained at pH 9 to 10 for a predetermined time. This facilitates dissolution of the succinic anhydride to promote the succinylation reaction.
- the yield of succinylation atelo collagen can be improved.
- the preparation method of esterified atelo collagen of one embodiment of the present invention is as follows.
- step 2) Adjust the pH of the atelo collagen dispersion obtained in step 1) to 7.4 using 0.1-0.5M NaOH and then centrifuge to obtain only acupuncture.
- step 2) The acupuncture obtained in step 2) is stirred in purified water at a rate of about 10-100 mL per 1 g, and then put in a dialysis membrane to perform dialysis in purified water.
- a reaction scheme showing a reaction in which the atelo collagen is esterified through the manufacturing process as described above is as follows.
- the dialysis using only purified water is performed to improve the yield and purity
- the method for producing the esterified atelo collagen according to one embodiment of the present invention ethanol or methanol
- the atelo collagen dispersion containing the atelo collagen was neutralized, centrifuged to obtain only sedimentation, and then dialysis was performed using a dialysis membrane to improve purity and yield.
- Example 3 the solubility of succinylated atelo collagen (anionized atelo collagen) obtained using the modified atelocollagen preparation method of one embodiment of the present invention was compared with conventional atelo collagen. As can be seen in the photograph of Figure 11, it can be seen that the succinylation atelocollagen prepared using the modified atelocollagen production method of the present invention shows a high solubility at neutral pH (pH 6.0 ⁇ 7.0).
- succinylated atelocollagen obtained by combining succinic anhydride with atelo collagen obtained using the modified atelocollagen production method according to an embodiment of the present invention has anionic properties and is lysed at neutral pH. Can improve adhesion, proliferation, and migration.
- esterified atelocollagen obtained by combining ethanol (or methanol) with atelocollagen obtained using the modified atelocollagen production method of one embodiment of the present invention is also dissolved at neutral pH and has cationic properties. It has the advantage that it can be combined more quickly and easily with the cell.
- high purity atelo collagen obtained through ultrafiltration and diafiltration is modified to be dissolved in neutral pH solution by succinylation and esterification so that collagen is not hydrolyzed by peptide or enzymatic treatment of collagen.
- the present invention uses the atelocollagen and the modified atelocollagen as described above to create a hard layer and a porous layer (two collagen layers having different porosities) and crosslink them to improve a three-dimensional matrix.
- the method for preparing a collagen-based matrix of the structure will be described in detail step by step.
- the collagen-based matrix included in the present invention is composed of a porous membrane and a double layer of hard membrane, and basically the porous membrane and hard membrane are obtained from the atelo collagen dispersion.
- the atelo collagen dispersion for preparing a porous membrane was prepared by adding the atelocollagen obtained in Example 1 corresponding to 1 to 3% by weight in distilled water, stirring and dispersing at 4 ° C. for 1 to 2 days, and then using a pH of 0.05 to 1N NaOH. Prepare by adjusting to 7.4.
- the atherocollagen dispersion for hard film preparation was prepared by adding the atelocollagen obtained in Example 1 to 2 to 5% by weight in distilled water, stirring and dispersing for 1 to 2 days at 4 ° C., and then dispersing 0.05 to 1N NaOH. Prepare by adjusting the pH to 7.4 by addition.
- Example 5-1 1) First, the atelocollagen dispersion for preparing the porous membrane prepared in Example 5-1 was diffused on a Petri dish or a plate of releasable form to form a uniform membrane in the range of 0.05 to 1 mm, and then at -60 to -80 ° C. Lyophilized in a lyophilizer for 1-2 days to prepare a porous membrane.
- Example 5-1 the atherocollagen dispersion for hard film preparation prepared in Example 5-1 was diffused to the bottom of the releasable flat plate, and a pressure of 1-20 psi was applied to prepare a hard film of 0.05-1 mm.
- step 3 the hard membrane obtained in step 2) is dried at room temperature for about 10-20 minutes, and then the porous membrane obtained in step 1) is lightly laminated thereon and air-dried at room temperature for 1 to 2 days to harden and porous membrane. The membranes are combined to obtain a double layer.
- the double film prepared in step 5) is cut from 200 ⁇ m ⁇ 200 ⁇ m ⁇ 200 ⁇ m to a maximum of 10 mm ⁇ 15 mm ⁇ 15 mm to complete the collagen-based matrix with improved utilization as a tissue restorative material.
- Example 5-2 the collagen-based matrix manufacturing method shown in Example 5-2 will be described in more detail.
- Example 5-1 1) First, the atelo collagen prepared in Example 5-1 corresponding to 2% by weight in distilled water was added thereto, maintained at 4 ° C., and stirred for 40 hours to obtain a collagen dispersion, and 0.5N NaOH was added to the dispersion to give pH. An atelo collagen dispersion for preparing a porous membrane adjusted to 7.4 was obtained. Then, add the atelo collagen prepared in Example 5-1 corresponding to 4% by weight in distilled water, and maintained at 4 ° C and stirred for 30 hours to disperse to obtain a collagen dispersion, 0.5N NaOH was added to the dispersion to pH 7.4 An adjusted atelo collagen dispersion for hard film production was obtained.
- the atelocollagen dispersion for preparing the porous membrane was diffused on a plate of releasability to form a uniform membrane of 0.5 mm, and then lyophilized for 30 hours in a freeze dryer maintained at -70 ° C to prepare a porous membrane.
- the collagen dispersion was diffused to the bottom of the releasable flat plate, and a pressure of 10 psi was applied to the porous adsorptive plate to prepare a 0.5 mm hard membrane.
- step 3 After drying the hard membrane obtained in step 2) at room temperature for 15 minutes, the porous membrane obtained in step 2) was lightly laminated thereon and air-dried at room temperature for 30 hours to combine the hard membrane and the porous membrane to obtain a double layer.
- EDC was added to a 95 wt% ethanol solution at a concentration of 50 mM and stirred at 4 ° C. for 15 minutes to obtain a mixed solution.
- step 5 After immersing the mixed solution obtained in step 4) to the degree of immersion of the double membrane obtained in step 3), the porous membrane and the hard membrane were crosslinked at 4 ° C. for 40 hours.
- glutaraldehyde was added at a ratio of 0.625% to 95% by weight of ethanol solution and stirred at 4 ° C. for 15 minutes to obtain a mixed solution.
- step 7) After immersing the mixed solution obtained in step 6) to the degree of immersion of the double membrane obtained in step 3), the porous membrane and the hard membrane were crosslinked at 4 ° C. for 4 hours.
- a double layer obtained in step 9) was cut from 200 ⁇ m ⁇ 200 ⁇ m ⁇ 200 ⁇ m to a maximum of 10 mm ⁇ 15 mm ⁇ 15 mm to prepare a collagen-based matrix having high utility as a tissue restorative material.
- atelo collagen and hyaluronic acid is added to hyaluronic acid
- a mucopolysaccharide mucopolysaccharide
- antibiotics such as penicillin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims (19)
- (a) 텔로펩타이드가 제거된 아텔로 콜라겐을 포함하는 시료를 용기 내에 준비하는 단계와,(b) 상기 아텔로 콜라겐을 포함하는 시료를 상기 용기로부터 여과 멤브레인이 구비된 여과모듈로 유입시키고, 상기 여과모듈에 압력을 인가하여 상기 시료가 상기 여과 멤브레인을 통과하면서 여과되도록 하는 한외여과 과정을 수행하는 단계와,(c) 상기 한외여과 과정을 통해 상기 여과 멤브레인을 통과하면서 여과되어 상기 여과모듈로부터 유출되는 아텔로 콜라겐 용액을 수집하는 단계와,(d) 상기 여과 멤브레인을 통과하면서 여과되는 아텔로 콜라겐 용액의 유량을 측정하여 한외여과 속도를 결정하는 단계와,(e) 상기 한외여과 속도가 일정한 속도 이하로 감소되면 상기 한외여과 과정을 중지하는 단계와,(f) 상기 시료 중 상기 여과 멤브레인을 통과하지 못하고 상기 용기로 복귀되는 잔류물에 물을 첨가한 후 이를 상기 여과 멤브레인이 구비된 여과모듈로 유입시켜 정용여과 과정을 수행하는 단계와,(g) 상기 정용여과 과정을 통해 상기 여과 멤브레인을 통과하면서 여과되어 상기 여과모듈로부터 유출되는 아텔로 콜라겐 용액을 수집하는 단계와,(h) 상기 (f) 단계와 상기 (g) 단계를 반복하는 단계를 포함하는 아텔로콜라겐 분리방법.
- 제1항에 있어서,상기 (b) 단계에서 펌프에 의한 펌핑 작용에 의해 상기 아텔로 콜라겐을 포함하는 시료를 상기 용기로부터 상기 여과 멤브레인이 구비된 여과모듈로 유입시키고, 상기 여과모듈에는 10~30psi의 압력을 인가하는 것을 특징으로 하는 아텔로콜라겐 분리방법.
- 제1항에 있어서,상기 (e) 단계에서 상기 한외여과 속도가 1g/분 이하로 감소되면 상기 한외여과 과정을 중지하는 것을 특징으로 하는 아텔로콜라겐 분리방법.
- 제1항에 있어서,상기 (f) 단계에서 상기 용기로 복귀되는 잔류물에는 한외여과 과정을 통해 여과된 용액과 동일한 양의 정제수를 첨가하는 것을 특징으로 하는 아텔로콜라겐 분리방법.
- 제1항에 있어서,상기 정용여과 과정은 적어도 5회 수행하는 것을 특징으로 하는 아텔로콜라겐 분리방법.
- 청구항 제1항 내지 제5항 중 어느 한 항에 정의된 아텔로콜라겐 분리방법에 따라 제조된 아텔로콜라겐.
- (a) 아텔로 콜라겐 용액에 숙신산 무수물을 넣어 반응시키고, 아텔로 콜라겐과 숙신산 무수물의 반응용액을 염기성 상태로 유지시키는 단계와,(b) 상기 아텔로 콜라겐과 숙신산 무수물의 반응용액을 저온에서 일정 시간 동안 교반하는 단계와,(c) 상기 (b) 단계에서 교반한 상기 아텔로 콜라겐과 숙신산 무수물의 반응용액을 일정 시간 동안 pH 9∼10 근처로 유지시키는 단계와,(d) 상기 아텔로 콜라겐과 숙신산 무수물의 반응용액에 산을 첨가하여 상기 반응용액을 산성 상태로 전환시켜 석시닐화 아텔로 콜라겐 침사를 형성하는 단계와,(e) 상기 석시닐화 아텔로 콜라겐 침사를 분리하여 수득하는 단계를 포함하는 석시닐화 아텔로 콜라겐 제조방법.
- 제7항에 있어서,상기 (b) 단계와 상기 (c) 단계는 적어도 4회 반복하는 것을 특징으로 하는 석시닐화 아텔로 콜라겐 제조방법.
- 제7항에 있어서,상기 석시닐화 아텔로 콜라겐 침사를 산성의 증류수로 세정하는 단계를 더 포함하는 석시닐화 아텔로 콜라겐 제조방법.
- 제7항에 있어서,상기 석시닐화 아텔로 콜라겐 침사를 동결건조하는 단계를 더 포함하는 석시닐화 아텔로 콜라겐 제조방법.
- 청구항 제7항 내지 제10항 중 어느 한 항에 정의된 석시닐화 아텔로 콜라겐 제조방법에 따라 제조된 석시닐화 아텔로 콜라겐.
- (a) 에탄올 또는 메탄올에 아텔로 콜라겐을 넣은 아텔로 콜라겐 분산액을 준비하고 산을 첨가하여 상기 아텔로 콜라겐 분산액을 산성 상태로 만든 후 교반하는 단계와,(b) 상기 (a) 단계에서 교반된 상기 아텔로 콜라겐 분산액을 중성 상태로 만드는 단계와,(c) 상기 (b) 단계에서 중성 상태로 된 상기 아텔로 콜라겐 분산액을 원심분리하여 에스테르화 아텔로 콜라겐 침사를 수득하는 단계와,(d) 상기 (c) 단계에서 수득된 에스테르화 아텔로 콜라겐 침사를 투석 멤브레인에 넣어 정제수 내에서 투석을 실시하는 단계를 포함하는 에스테르화 아텔로 콜라겐 제조방법.
- 제12항에 있어서,상기 (d) 단계에서 투석된 에스테르화 아텔로 콜라겐 침사를 동결건조하는 단계를 더 포함하는 에스테르화 아텔로 콜라겐 제조방법.
- 청구항 제12항 또는 청구항 제13항에 정의된 에스테르화 아텔로 콜라겐 제조방법에 따라 제조된 에스테르화 아텔로 콜라겐.
- (a) 청구항 제1항 내지 제5항 중 어느 한 항에 정의된 아텔로콜라겐 분리방법에 의해 수득한 아텔로 콜라겐 분산액을 일정한 두께로 확산시켜 일정 두께의 균일한 막을 형성한 후 이를 동결건조시켜 콜라겐 다공성층을 형성하는 단계와,(b) 청구항 제1항 내지 제5항 중 어느 한 항에 정의된 아텔로콜라겐 분리방법에 의해 수득한 아텔로 콜라겐 분산액을 일정한 두께로 확산시키고 다공성의 흡착판으로 압력을 가해서 수분은 침출시키고 콜라겐 입자들은 밀착시켜 조직이 치밀한 콜라겐 경질층을 형성하는 단계와,(c) 상기 (b) 단계에서 형성된 콜라겐 경질층 상에 상기 (a) 단계에서 형성된 콜라겐 다공성층을 적층시키고 풍건하여 상기 콜라겐 경질층과 상기 콜라겐 다공성층을 1차적으로 결합시키는 단계와,(d) 상기 (c) 단계를 통해 1차적으로 결합된 상기 콜라겐 경질층과 상기 콜라겐 다공성층을 가교화 수단을 이용하여 가교화시킴으로써 상기 콜라겐 경질층과 상기 콜라겐 다공성층을 2차적으로 결합시키는 단계를 포함하는 콜라겐 기반 매트릭스의 제조방법.
- 제15항에 있어서,상기 가교화 수단은 EDC[1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide] 또는 글루타르알데히드인 것을 특징으로 하는 콜라겐 기반 매트릭스의 제조방법.
- 제15항에 있어서,상기 가교화 수단이 가교화제인 경우 가교화제를 세정하는 단계를 더 포함하고, 가교화제를 세정한 후 상기 콜라겐 경질층과 상기 콜라겐 다공성층의 이중층을 추가로 동결건조하는 것을 특징으로 하는 콜라겐 기반 매트릭스의 제조방법.
- 제15항에 있어서,상기 (a) 단계에서 사용되는 아텔로 콜라겐 분산액에는 히알루론산이 첨가되는 것을 특징으로 하는 콜라겐 기반 매트릭스의 제조방법.
- 청구항 제15항 내지 제18항 중 어느 한 항에 정의된 콜라겐 기반 매트릭스의 제조방법에 따라 제조된 콜라겐 기반 매트릭스.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180028248.3A CN102933595B (zh) | 2010-05-14 | 2011-04-21 | 去端肽胶原及其分离方法、改性去端肽胶原及其制备方法、胶原型基质 |
US13/698,017 US20130071645A1 (en) | 2010-05-14 | 2011-04-21 | Method for separating atelocollagen, method for preparing modified atelocollagen, atelocollagen prepared by using the same and collagen-based matrix |
HK13108459.2A HK1181056A1 (en) | 2010-05-14 | 2013-07-18 | Atelocollagen separation method, method for preparing modified atelocollagen, and atelocollagen-and collagen-based matrix prepared by the methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0045322 | 2010-05-14 | ||
KR1020100045322A KR101158338B1 (ko) | 2010-05-14 | 2010-05-14 | 아텔로콜라겐 분리방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011142543A2 true WO2011142543A2 (ko) | 2011-11-17 |
WO2011142543A3 WO2011142543A3 (ko) | 2012-05-31 |
Family
ID=44914790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/002903 WO2011142543A2 (ko) | 2010-05-14 | 2011-04-21 | 아텔로콜라겐 분리방법 및 개질된 아텔로콜라겐 제조방법 그리고 이를 이용하여 제조된 아텔로콜라겐 및 콜라겐 기반 매트릭스 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130071645A1 (ko) |
KR (1) | KR101158338B1 (ko) |
CN (1) | CN102933595B (ko) |
HK (1) | HK1181056A1 (ko) |
WO (1) | WO2011142543A2 (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101327630B1 (ko) * | 2012-03-05 | 2013-11-13 | 울산대학교 산학협력단 | 아텔로콜라겐을 이용한 췌도세포 이식용 담체의 제조방법 그리고 이를 이용하여 제조된 인공췌장 |
RU2665962C1 (ru) | 2017-03-17 | 2018-09-05 | Общество с ограниченной ответственностью "Матрифлекс" | Биорезорбируемый биологический матрикс для замещения дефектов костной ткани и способ его получения |
GB201708853D0 (en) * | 2017-06-02 | 2017-07-19 | Jellagen Pty Ltd | Method |
TWI770078B (zh) * | 2017-11-10 | 2022-07-11 | 惠合再生醫學生技股份有限公司 | 膠原蛋白處理方法 |
GB201808106D0 (en) * | 2018-05-18 | 2018-07-04 | Cambridge Entpr Ltd | Collagen biomaterials and methods for manufacturing collagen biomaterials |
WO2022055269A1 (ko) * | 2020-09-10 | 2022-03-17 | 주식회사 한국유니온 생명과학 | 고순도 및 고수율로 제조된 아텔로콜라겐 제조방법 및 이의 용도 |
CN113201569B (zh) * | 2021-06-21 | 2022-08-30 | 江南大学 | 一种牛ⅰ型胶原蛋白的纯化方法 |
CN114053166B (zh) * | 2021-11-08 | 2022-07-08 | 浙江崇山生物制品有限公司 | 一种酰化ⅰ型胶原蛋白水光针的制备方法 |
CN116808279B (zh) * | 2023-08-25 | 2023-11-21 | 北京国械堂科技发展有限责任公司 | 一种亲水性复合胶原蛋白海绵及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4748152A (en) * | 1985-01-22 | 1988-05-31 | Opticol Corp. | Succinylated atelocollagen solution for use in viscosurgery and as a vitreous substitute |
KR20020029859A (ko) * | 2000-10-14 | 2002-04-20 | 지귀환 | 제 1 형 아텔로교원질의 직접 분리추출 방법 |
KR20030072512A (ko) * | 2002-03-04 | 2003-09-15 | 이재관 | 유기용매를 이용한 가용성 콜라겐의 제조방법 |
KR100676285B1 (ko) * | 2005-03-11 | 2007-01-30 | 세원셀론텍(주) | 동물의 다양한 조직으로부터의 콜라겐 분리방법 및 콜라겐 용액의 제조방법 그리고 이를 이용하여 생산한 매트릭스 |
KR100875136B1 (ko) * | 2008-04-16 | 2008-12-22 | 주식회사 다림바이오텍 | 돼지 유래 에스터화 아텔로콜라겐을 이용한 접착성 지혈제및 그 제조방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6028936A (ja) * | 1983-07-27 | 1985-02-14 | Koken:Kk | アテロコラ−ゲン水溶液およびその製造方法 |
US5597486A (en) * | 1995-05-01 | 1997-01-28 | Millipore Investment Holdings Limited | Membrane filtration with optimized addition of second liquid to maximize flux |
US6673370B2 (en) * | 2001-05-15 | 2004-01-06 | Biomedicines, Inc. | Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
-
2010
- 2010-05-14 KR KR1020100045322A patent/KR101158338B1/ko active IP Right Grant
-
2011
- 2011-04-21 US US13/698,017 patent/US20130071645A1/en not_active Abandoned
- 2011-04-21 CN CN201180028248.3A patent/CN102933595B/zh active Active
- 2011-04-21 WO PCT/KR2011/002903 patent/WO2011142543A2/ko active Application Filing
-
2013
- 2013-07-18 HK HK13108459.2A patent/HK1181056A1/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4748152A (en) * | 1985-01-22 | 1988-05-31 | Opticol Corp. | Succinylated atelocollagen solution for use in viscosurgery and as a vitreous substitute |
KR20020029859A (ko) * | 2000-10-14 | 2002-04-20 | 지귀환 | 제 1 형 아텔로교원질의 직접 분리추출 방법 |
KR20030072512A (ko) * | 2002-03-04 | 2003-09-15 | 이재관 | 유기용매를 이용한 가용성 콜라겐의 제조방법 |
KR100676285B1 (ko) * | 2005-03-11 | 2007-01-30 | 세원셀론텍(주) | 동물의 다양한 조직으로부터의 콜라겐 분리방법 및 콜라겐 용액의 제조방법 그리고 이를 이용하여 생산한 매트릭스 |
KR100875136B1 (ko) * | 2008-04-16 | 2008-12-22 | 주식회사 다림바이오텍 | 돼지 유래 에스터화 아텔로콜라겐을 이용한 접착성 지혈제및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
CN102933595A (zh) | 2013-02-13 |
CN102933595B (zh) | 2015-01-21 |
KR20110125772A (ko) | 2011-11-22 |
KR101158338B1 (ko) | 2012-06-22 |
HK1181056A1 (en) | 2013-11-01 |
US20130071645A1 (en) | 2013-03-21 |
WO2011142543A3 (ko) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011142543A2 (ko) | 아텔로콜라겐 분리방법 및 개질된 아텔로콜라겐 제조방법 그리고 이를 이용하여 제조된 아텔로콜라겐 및 콜라겐 기반 매트릭스 | |
US10421777B2 (en) | Process for extraction of fish collagen and formulations of 3D matrices of collagen for biomedical and therapeutic applications thereof | |
US9315562B2 (en) | High-strength collagen fiber membrane and a manufacturing method thereof | |
JP4463702B2 (ja) | 伸縮性コラーゲン成形体、その製造方法および用途 | |
US20130130384A1 (en) | Temperature responsive sheet that displays reversible properties and cell sheet production method using same | |
US20090312524A1 (en) | Compositions and methods comprising collagen | |
ITMI20001794A1 (it) | Membrane di collagene a due facce di cui una organizzata a livello macromolecolare. | |
WO2012144719A1 (ko) | 펩타이드에 의한 표면활성형 콜라겐 차폐막 | |
KR20130118418A (ko) | 생체조직 유래 소재의 탈세포 처리제, 이를 이용한 처리방법 및 이로부터 수득된 생체 재료 | |
EP4011411A1 (en) | Preparation method for silk fibroin nerve graft fused with nt3 | |
WO2012081944A2 (en) | Dental membrane and method of manufacturing the same | |
KR101188164B1 (ko) | 숙시닐화 아텔로 콜라겐 제조방법 | |
WO2022014769A1 (ko) | 수화형태 무세포화 피부대체재 및 그 제조방법 | |
US8263135B2 (en) | Process for isolating biomaterial from tissue and an isolated biomaterial extract prepared therefrom | |
KR100465015B1 (ko) | 유기용매를 이용한 가용성 콜라겐의 제조방법 | |
WO2021040141A1 (ko) | 동물지방 유래 세포외기질 및 동물지방 유래 세포외기질 보존액 | |
WO2013042868A1 (en) | Method of obtaining silkworm gland-derived hydrolysate | |
US20220298226A1 (en) | Methacrylated collagen | |
WO2017065368A1 (ko) | 키토올리고당을 함유하는 피부조직재생용 세포담체 및 그 제조방법 | |
KR101188167B1 (ko) | 에스테르화 아텔로 콜라겐 제조방법 | |
JP2007124901A (ja) | コラーゲン抽出方法 | |
US8389010B2 (en) | Stretchable collagen material and manufacturing method and use thereof | |
WO2022138992A1 (ko) | 무세포 신경 이식재 및 그 제조방법 | |
WO2022149944A1 (ko) | 오가노이드 배양을 위한 탈세포 지방 조직 유래 지지체 및 이의 제조방법 | |
WO2022055269A1 (ko) | 고순도 및 고수율로 제조된 아텔로콜라겐 제조방법 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180028248.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11780760 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13698017 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3840/KOLNP/2012 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11780760 Country of ref document: EP Kind code of ref document: A2 |